

Fax completed form to: (855) 840-1678 If this is an URGENT request, please call (800) 882-4462

(800.88.CIGNA)

Durolane, Euflexxa, Gel-One, Gelsyn 3, GenVisc 850, Hyalgan, Hymovis, Monovisc, Orthovisc, sodium hyaluronate 1% injection, Supartz FX, Synojoynt, Synvisc, Synvisc-One, Triluron, Trivisc, Visco-3

PHYSICIAN	PATIENT INFORMATION						
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax				
Specialty:	* DEA, NPI or	TIN:	with the outcome of our review unless all asterisked (*) items on this form are completed.*				
Office Contact Person:			* Patient Name:				
Office Phone:			* Cigna ID: * Date of Birth:				
Office Fax:			* Patient Street Address:				
Office Street Address:			City:	Sta	ate:	Zip:	
City:	State:	Zip:	Patient Phone:				
Urgency: Standard Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)							
Medication Requested:] Durolane] Hyalgan njection] Triluron] Visco-3	☐ Euflexx ☐ Hymov ☐ Supart	is 🗌 N	Gel-One Aonovisc Synojoyn] Gelsyn 3] Orthovisc] Synvisc	
Please specify site of injection for this request: ☐ left knee ☐ Other:			☐ right knee ☐ both knees				
Quantity: Duration of therapy:		Jcod	Jcode:		ICD10:		
(if Euflexxa, Gelsyn-3, GenVisc 850, Hyalgan, Hymovis, Orthovisc, sodium hyaluronate 1% injection, Supartz FX, Synojoynt, Triluron, Trivisc or Visco-3) The drug you're requesting is given as a series of weekly injections. Has your patient already started a course of injections with the requested drug?							
Please specify drug, sites of injection (one or both knees) and date(s) of injection.							
Is this a new start or continua ☐ New Start ☐ Continuation of therapy	ation of therapy	?					
(if continuation of therapy) Please indicate the date(s) of the last injection(s) of intra-articular hyaluronic acid products your patient received, including the injection site(s) and product(s) used.							
(if continuation of therapy) H	as it been 6 mo	nths or longer since	the last injection or in	jection s	eries?	🗌 Yes 🗌 No	
(if continuation of therapy) D therapy?	id your patient ł	nave a documented b	oeneficial response si	nce initia	ating Intraarticula	r Hyaluronic Acid ☐ Yes	
(Please note: there are different resource [e.g. cignaforhcp.com]						alth care professional	

Where will this medicat Accredo Specialty Pharr Prescriber's office stock Other (please specify):		 Retail pharmacy Home Health / Home Infusion **Cigna's nationally preferred spectrum 	
	placed with Accredo via E-prescribe - Ac 8.302.1028, or Verbal 866.759.1557	credo (1620 Century Center Pkwy, Memphis, Tr	N 38134-8822
Is the requested medication the patient?	n for a chronic or long-term condition for w	hich the prescription medication may be necess	sary for the life of ☐ Yes ☐ No
	e Pathologic Conditions Involving Joints O f the Knee Other than Osteoarthritis	ther than the Knee	
	s been documented by radiologic evidenc erosis, osteophytes, subchondral cysts)?	e of osteoarthritis of the knee (for example, join	t space ☐ Yes ☐ No
2. At least TWO of the follow acetaminophen, tramadol, a	vider-directed conservative management wing pharmacologic therapies: oral or top	program consisting of physical therapy or home ical nonsteroidal anti-inflammatory drug(s) [NSA ed knee?	
How many of the above the Two or more of the above One of the above	rapies did the patient have failure to?		
Please provide names of m and response to above ther		s tried, or corticosteroids used, including date(s)	, duration of use,
			🗌 Yes 🗌 No
(if yes) How many of the ab ☐ All three of the above ☐ Two of the above ☐ One of the above ☐ None of the above	ove therapies does the patient have a do	cumented contraindication or intolerance to?	
Please provide specific deta	ails on the patient's contraindication or int	olerance to the above therapies.	
Will the patient be using pla viscosupplement injection?	telet rich plasma (PRP), stem cell produc	ts, amniotic products, corticosteroids with the re	equested □ Yes □ No
The covered alternatives* a i. Euflexxa; and ii. Durolane or Gelsyn-3.	re:		
were of taking each drug, in		te(s) taken and for how long, and what the docu tions your patient experienced. For the alternati d prior auth.	

For Euflexxa, per the information provided above, which of the following is true for your patient? The patient tried this alternative, but it didn't work The patient tried this alternative, but they did not tolerate it The patient cannot try the alternative because of a contraindication to this drug Other
For Durolane or Gelsyn-3, per the information provided above, which of the following is true for your patient? The patient tried one of these alternatives, but it didn't work The patient tried one of these alternatives, but they did not tolerate it The patient cannot try the alternative because of a contraindication to this drug Other
Please provide any additional pertinent clinical information, including: if the patient is currently on the requested drug (with dates of use) and how they have been receiving it (samples, out of pocket, etc).
Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.
Prescriber Signature: Date:
Save Time! Submit Online at: www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.
Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

v011524

V01152 "Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005